

26. Seiwert TY, Fayette J, Cupissol D et al (2014) A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. *Ann Oncol* 25:1813–1820
27. Smith C, Tsang J, Beagley L et al (2012) Effective treatment of metastatic forms of Epstein-Barr virus-associated Nasopharyngeal carcinoma with a novel Adenovirus-based adoptive immunotherapy. *Cancer Res* 72(5):1116–1125
28. Taylor GS, Jia H, Harrington K et al (2014) A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. *Clin Cancer Res* 20:5009–5022
29. Thierauf J, Veit JA, Affolter A et al (2015) Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck. *Melanoma Res* 25:503–509
30. Timar J, Forster-Horvath C, Lukits J et al (2003) The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer—a multicenter phase I/II clinical trial. *Laryngoscope* 113:2206–2217
31. Uyttenhove C, Pilotte L, Theate I et al (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. *Nat Med* 9:1269–1274
32. Van Der SSJ, Davies DM, Wilkie S et al (2013) Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity? *J Immunol* 191:4589–4598
33. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. *Lancet Oncol* 14:697–710
34. Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer genome landscapes. *Science* 339:1546–1558
35. Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 369:122–133
36. Yoshitake Y, Fukuma D, Yuno A et al (2015) Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. *Clin Cancer Res* 21:312–321
37. Zandberg DP, Rollins S, Goloubeva O et al (2015) A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). *Cancer Immunol Immunother* 64:367–379

HNO 2016 · 64:478
 DOI 10.1007/s00106-016-0189-8
 © Springer-Verlag Berlin Heidelberg 2016



J. Zirkler¹ · T. Rahne¹ · C. Lautenschläger² · R. Honigmann¹ · S. K. Plontke¹

¹ Universitätsklinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Deutschland

² Institut für Medizinische Epidemiologie, Biometrie und Informatik, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Deutschland

Erratum zu: Ballondilatation der Tuba auditiva bei Mittelohroperationen

Studienplanung und erste Erfahrungen bei der Rekrutierung

Erratum zu:
 HNO (2016) 64:237–242
 DOI 10.1007/s00106-016-0146-6

Dieser Beitrag ist leider in der Rubrik „Originalien“ statt in der Rubrik „Leitthema“ erschienen. Wir bitten, dies zu entschuldigen.

Die Redaktion

Korrespondenzadresse

Prof. Dr. S. K. Plontke

Universitätsklinik und Poliklinik für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie, Martin-Luther-Universität Halle-Wittenberg
 Ernst-Grube-Str. 40, 06120 Halle (Saale),
 Deutschland
 stefan.plontke@uk-halle.de

Die Online-Version des Originalbeitrags ist unter
 DOI 10.1007/s00106-016-0146-6 zu finden.